Proliferative nodules in congenital melanocytic nevi: A clinicopathologic and immunohistochemical analysis

American Journal of Surgical Pathology

Volumn 28, Issue 8, 2004, Pages 1017-1025

  Herron, Mark D ^a   Vanderhooft, Sheryll L ^a   Smock, Kristi ^a   Zhou, Holly ^a   Leachman, Sancy A ^b   Coffin, Cheryl ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Congenital melanocytic nevus; Giant congenital nevus; Nodular melanocytic proliferation; Proliferative nodules; Pseudotumoral proliferative nodule

Indexed keywords

CD45 ANTIGEN; FAS ANTIGEN; KI 67 ANTIGEN; MELAN A; MYC PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEIN S 100; STEM CELL FACTOR;

APOPTOSIS; CANCER RISK; CELL MATURATION; CLINICAL ARTICLE; CONGENITAL MELANOCYTIC NEVUS; DISEASE COURSE; FEMALE; FOLLOW UP; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MALIGNANT TRANSFORMATION; MELANOCYTE; MELANOCYTIC NEVUS; MELANOMA; NEWBORN; OUTCOMES RESEARCH; PROLIFERATIVE NODULE; PROTEIN EXPRESSION; REVIEW; SKIN BIOPSY; SKIN NODULE; TUMOR CLASSIFICATION; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CELL DIVISION; CELL NUCLEUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; MALE; MELANOCYTES; NEVUS, PIGMENTED; PRECANCEROUS CONDITIONS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 3242815178     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pas.0000126785.61609.6e     Document Type: Review

References (45)

1. Alper J, Holmes LB, Mihm MC Jr. Birthmarks with serious medical significance: nevocellular nevi, sebaceous nevi, and multiple cafe au lait spots. J Pediatr. 1979;95:696-700.
2. Alper JC, Holmes LB. The incidence and significance of birthmarks in a cohort of 4,641 newborns. Pediatr Dermatol. 1983;1:58-68.
3. Barnhill RL, Fleischli M. Histologic features of congenital melanocytic nevi in infants 1 year of age or younger. J Am Acad Dermatol. 1995;33:780-785.
4. Bastian BC. Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer. Oncogene. 2003;22:3081-3086.
5. Bastian BC, Xiong J, Frieden IJ, et al. Genetic changes in neoplasms arising in congenital melanocytic nevi: differences between nodular proliferations and melanomas. Am J Pathol. 2002; 161:1163-1169.
6. Bittencourt FV, Marghoob AA, Kopf AW, et al. Large congenital melanocytic nevi and the risk for development of malignant melanoma and neurocutaneous melanocytosis. Pediatrics. 2000;106:736-741.
7. Borbujo J, Jara M, Cortes L, et al. A newborn with nodular ulcerated lesion on a giant congenital nevus. Pediatr Dermatol. 2000;17:299-301.
8. Borner C, Schlagbauer Wadl H, Fellay I, et al. Mutated N-ras upregulates Bcl-2 in human melanoma in vitro and in SCID mice. Melanoma Res. 1999;9:347-350.
9. Bowen AR, Hanks AN, Allen SM, et al. Apoptosis regulators and responses in human melanocytic and keratinocytic cells. J Invest Dermatol. 2003; 120:48-55.
10. Cerroni L, Soyer HP, Kerl H. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am J Dermatopathol. 1995; 17:7-11.
11. Crowson AN, Mihm MC, Magro CM. The Melanocytic Proliferations: A Comprehensive Textbook of Pigmented Lesions. New York: Wiley-Liss, 2001.
12. de Vooght A, Vanwijck R, Gosseye S, et al. Pseudo-tumoral proliferative nodule in a giant congenital naevus. Br J Plast Surg. 2003;56:164-167.
13. Dean NR, Brennan J, Haynes J, et al. Immunohistochemical labeling of normal melanocytes. Appl Immunohistochem Mol Morphol. 2002; 10: 199-204.
14. Elder DE, Murphy GF, et al. Pathology. In: Melanocytic Tumors of the Skin. Washington, DC: Armed Forces Institute of Pathology, 1991.
15. Evans MJ, Sanders DS, Grant JH, et al. Expression of Melan-A in Spitz, pigmented spindle cell nevi, and congenital nevi: comparative immunohistochemical study. Pediatr Dev Pathol. 2000;3:36-39.
16. Florell SR, Boucher KM, Holden JA, et al. Failure to detect differences in proliferation status of nevi from CDKN2A mutation carriers and noncarriers. J Invest Dermatol. 2002;118:386-387.
17. Giam YC, Williams ML, Leboit PE, et al. Neonatal erosions and ulcerations in giant congenital melanocytic nevi. Pediatr Dermatol. 1999; 16:354-358.
18. Halaban R. The regulation of normal melanocyte proliferation. Pigment Cell Res. 2000; 13:4-14.
19. Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CDI 17) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol. 2002;117:188-193.
20. Huang S, Jean D, Luca M. et al. Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J. 1998;17:4358-4369.
21. Kanter-Lewensohn L, Hedblad MA, Wejde J, et al. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas. Mod Pathol. 1997;10:917-920.
22. Kaplan EN. Malignant potential of large congenital nevi. West J Med. 1974;121:226.
23. Kuwata T, Kitagawa M, Kasuga T. Proliferative activity of primary cutaneous melanocytic tumours. Virchows Arch A Pathol Anat Histopathol. 1993;423:359-364.
24. Leech SN, Bell H, Leonard N, et al. Neonatal giant congenital nevi with proliferative nodules: a clinicopathologic study and literature review of neonatal melanoma. Arch Dermatol. 2004;140:83-88.
25. Lowes MA, Norris D, Whitfeld M. Benign melanocytic proliferative nodule within a congenital naevus. Australas J Dermatol. 2000;41:109-111.
26. Luca MR, Bar-Eli M. Molecular changes in human melanoma metastasis. Histol Histopathol. 1998; 13:1225-1231.
27. Luo R, Gao J, Wehrle-Haller B. et al. Molecular identification of distinct neurogenic and melanogenic neural crest sublineages. Development. 2003;130:321-330.
28. Mancianti ML, Clark WH, Hayes FA, et al. Malignant melanoma simulants arising in congenital melanocytic nevi do not show experimental evidence for a malignant phenotype. Am J Pathol. 1990; 136:817-829.
29. Montone KT, van Belle P, Elenitsas R, et al. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol. 1997;10:939-944.
30. Morales-Ducret CR, van de Rijn M, Smoller BR. bcl-2 expression in melanocytic nevi: insights into the biology of dermal maturation. Arch Dermatol. 1995;131:915-918.
31. Ohashi A, Funasaka Y, Ueda M, et al. c-KIT receptor expression in cutaneous malignant melanoma and benign melanotic naevi. Melanoma Res. 1996;6:25-30.
32. Papp T, Pemsel H, Zimmermann R, et al. Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MCIR genes in human congenital melanocytic naevi. J Med Genet. 1999;36:610-614.
33. Piepkorn M. Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors. J Am Acad Dermatol. 2000;42: 705-722; quiz 723-726.
34. Potti A, Moazzam N, Langness E, et al. Immunohistochemical determination of HER-2/neu, c-Kit (CDI 17), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma. J Cancer Res Clin Oncol. 2004;130:80-86.
35. Reyes-Mugica M, Alvarez-Franco M, Bauer BS, et al. Nevus cells and special nevomelanocytic lesions in children. Pediatr Pathol. 1994; 14: 1029-1041.
36. Rhodes AR, Wood WC, Sober AJ, et al. Nonepidermal origin of malignant melanoma associated with a giant congenital nevocellular nevus. Plast Reconstr Surg. 1981;67:782-790.
37. Ribe A, McNutt NS. S-100A6 protein expression is different in Spitz nevi and melanomas. Mod Pathol. 2003; 16:505-511.
38. Roth ME, Grant-Kels JM. Important melanocytic lesions in childhood and adolescence. Pediatr Clin North Am. 1991;38:791-809.
39. Ruiz-Maldonado R, del Rosario Barona-Mazuera M, Hidalgo-Galvan LR. et al. Giant congenital melanocytic nevi, neurocutaneous melanosis and neurological alterations. Dermatology. 1997; 195:125-128.
40. Seykora JT, Jih D, Elenitsas R, et al. Gene expression profiling of melanocytic lesions. Am J Dermatopathol. 2003;25:6-11.
41. Tokuda Y, Mukai K, Matsuno Y, et al. Proliferative activity of cutaneous melanocytic neoplasms defined by a proliferating cell nuclear antigen labelling index. Arch Dermatol Res. 1992;284:319-323.
42. Tran TA, Ross JS, Carlson JA, et al. Mitotic cyclins and cyclin-dependent kinases in melanocytic lesions. Hum Pathol. 1998;29:1085-1090.
43. Wehrle-Haller B. The role of kit-ligand in melanocyte development and epidermal homeostasis. Pigment Cell Res. 2003; 16:287-296.
44. Xu X, Weber KS, Elenitsas R, et al. Cellular nodules in congenital melanocytic nevi. In: Eble JN, ed. United States and Canadian Academy of Pathology. Chicago: Lippincott Williams & Wilkins, 2002:112A.
45. Yoshida H, Kunisada T, Grimm T, et al. Review: melanocyte migration and survival controlled by SCF/c-kit expression. J Invest Dermatol Symp Proc. 2001;6:1-5.